Skip to main content

Table 3 Antiviral activities of the title compounds against TMV in vivo at 500 μg/mL

From: Synthesis and biological activity of myricetin derivatives containing 1,3,4-thiadiazole scaffold

Compd. Curative activity (%) Protection activity (%) Compd. Curative activity (%) Protection activity (%)
2 18.2 ± 7.3 21.5 ± 9.1 3j 28.7 ± 3.8 39.4 ± 3.1
3a 46.7 ± 5.2 50.3 ± 9.3 3k 28.0 ± 8.6 33.0 ± 7.5
3b 53.8 ± 9.0 54.1 ± 9.4 3l 33.9 ± 9.4 34.2 ± 5.4
3c 37.0 ± 9.1 58.4 ± 1.0 3m 57.1 ± 9.6 56.7 ± 8.2
3d 59.8 ± 9.2 54.3 ± 9.0 3n 48.4 ± 5.9 42.1 ± 7.1
3e 28.7 ± 8.3 35.4 ± 5.1 3o 50.8 ± 3.6 47.3 ± 2.9
3f 68.4 ± 7.4 54.4 ± 7.7 3p 34.6 ± 5.4 36.5 ± 1.6
3g 36.4 ± 3.8 38.6 ± 7.7 Myricetin a 28.8 ± 6.7 34.4 ± 7.2
3 h 44.8 ± 9.4 45.2 ± 1.5 Ningnanmycin a 51.8 ± 4.3 58.3 ± 2.9
3i 66.8 ± 9.8 60.8 ± 8.3    
  1. Average of three replicates
  2. aNingnanmycin and myricetin were used for comparison of antiviral activity